Camizestrant: Data from P3 CAMBRIA-1 trial (NCT05774951) for ER+/HER2-negative early breast cancer after at least 2 years of standard adjuvant endocrine therapy post 2026 (AstraZeneca) - Apr 29, 2025 - Q1 2025 Results: Data from P3 CAMBRIA-2 trial (NCT05952557) for ER+/HER2-negative early breast cancer post 2026
P3 data • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Negative Breast Cancer • Oncology
|